There is a lack of evidence on the clinical efficacy and safety of the recently released Chinese botulinum toxin serotype A (Prosigne) for the treatment of focal dystonias and hemifacial spasm.
B
otulinum toxin type A (btxA) has been accepted as the first treatment choice for blepharospasm and hemifacial spasm because of its efficacy and safety profile.
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However, there is lack of data regarding the role of the Chinese btxA and how it compares to other btxA formulations. To date, only 1 clinical study retrospectively compared Prosigne with Botox for focal dystonias and hemifacial spasm and found no significant differences. 4 However, its findings are questionable because of methodological aspects.
METHODS AND PATIENTS
A double-blind crossover trial was performed, and the results were reported according to formal recommendations. 5 Patients were consecutively recruited from our movement disorders clinic (Hospital de Clínicas de Porto Alegre, Brazil) and independently randomized from the pharmacy department to one treatment sequence (Prosigne, Lanzhou Biological Products Institute, followed by Botox, Allergan Pharmaceuticals) or another (Botox followed by Prosigne). All patients gave their written informed consent for participating in the study, which was approved by the ethical committee of our institution.
Inclusion and Exclusion Criteria
Patients with primary blepharospasm or hemifacial spasm were eligible if they were older than 18 years and had benefit from the last btxA treatment that was always Botox. Benefit was defined as at least a significant improvement according to both patient and physician impressions determined by using a visual analog scale (VAS) ranging from 0 (worsening) to 5 (marked improvement). Significant improvement was considered present if both patient and physician scored at least 8 points in the VAS and none scored less than 4 (significant 
Treatment, Dose Regimen, and Titration
Patients were randomized to Botox at the usually effective dose or Prosigne, at a ratio of 1:1 (1 Botox unit = 1 Prosigne unit). Both btxAs were diluted with sterile sodium chloride (5 U/0.1 mL). The dose of btxA per injection site was 2.5 to 5 U. Preparation and administration of btxA were made blindly by 2 independent investigators. Location, number of injections sites, and dose of each treatment session were maintained in both periods.
Outcome Measures
Patients were evaluated before injections and 4 and 12 weeks after each session. Appointment for reinjection was based on the patient's need for treatment but not before 12 weeks from the last injection. Primary outcome was assessed by the patients by means of a VAS (Patient Global Assessment of Change), in which improvement was subjectively measured from 0% to 100%. Other efficacy variables assessed were as follows: onset of response (time interval between the injection and the first sign of improvement after treatment) and duration of effect (time interval between the first detectable clinical effect and the moment that the patient felt need for retreatment). These 2 outcomes were also assessed by the patients using a standardized diary where patients were asked to mark daily if there was any subjective sign of improvement (and which sign) or if they felt the need for retreatment (and the reason why). In addition, patients were also questioned about in which treatment period (first or second injection) they achieved the best response. Adverse effects were assessed through a structured questionnaire addressing the most common known adverse effects of btx.
Statistical Analysis
The sample size was estimated empirically based on the results of previous similar studies. 6 
RESULTS
Initially, a total of 28 patients was randomized to treatment. There were 2 withdrawals (1 from each group) after the first btxA treatment due to unknown reasons. Most of our patients had hemifacial spasm (69.2%). The demographic and clinical characteristics of the patients are summarized in Table 1 .
There were no differences between the 2 btxA formulations for all efficacy and safety outcome measures (Table 2) . Regarding the outcome of the treatment period of best response, 5 patients did not perceive any difference between the 2 btxAs. The 2 most common adverse effects reported similarly in both groups were mild ptosis and local ecchymoses, all being transitory and well tolerated. The occurrence of other adverse effects was similar between both drugs (Table 3 ). There were no serious adverse events.
DISCUSSION
This is the first double-blind, randomized, crossover study comparing Prosigne versus Botox. To date, only 1 study had evaluated Prosigne. 4 This was a retrospective study that aimed to compare Prosigne with Botox based on a series of 785 patients with hemifacial spasm and many types of focal dystonias, including blepharospasm. As in our study, this retrospective series did not find significant differences between the 2 btxA formulations. The availability of the most common btxAs to treat dystonias and hemifacial spasm has led to a debate concerning the comparative effectiveness and safety and the dose equivalency ratio that should be used in clinical practice. 8 In our study, we used equivalent units of Botox and Prosigne, and we found similar results with both drugs, suggesting a direct equivalence between them. This is not in agreement with Tan and Wan 4 who found equivalence at a ratio of 1:1.5 between Botox and Prosigne. This discrepancy could be related to the heterogeneity of their patients and to the retrospective design of the study by Tan and Wan. 4 Different formulations of btx are considered not bioequivalent, and further randomized studies are needed to establish the clinical comparability of Prosigne with other btxA formulations. 8 Because of the great individual variability of signs and symptoms in patients with blepharospasm and hemifacial spasm, we decided to use a crossover design in which each patient acted as his own control. In order to avoid inherent design biases, we used a standardized protocol for injections and the same volume and units in each of the 2 treatments. However, our study still has important limitations. First, although subjective evaluations may be more relevant when assessing the efficacy of treatment of dystonias, we have not used objective scales for documenting the clinical evolution of the patients. Second, inherent problems related to crossover designs could have happened in our study, such as the carryover effect. In this case, because the patients were not treated for the first time with btxA, some of the efficacy attributable to Prosigne could simply be related to residual effects of previously administered Botox. However, the baseline severity at the beginning of the second crossover period was similar to the baseline severity at the study entry, which suggests that this potential bias was not present. Third, we have enrolled a relatively small number of patients, and the similarity of efficacy and safety profiles between the 2 btx formulations observed could be explained by the fact that our study was not powerful enough to detect differences. However, the similar SDs of our results do not suggest that a type II error has occurred. Fourth, we have not included patients with other type of focal dystonias besides blepharospasm, and the results found here cannot be directly extrapolated to other conditions. Finally, because of the short-term follow-up of the patients, we have not addressed other important topics when comparing different btx formulations, such as the immunogenic potential.
In conclusion, despite the limitations of this study, our results suggest that Prosigne and Botox are comparable in shortterm efficacy and safety in the treatment of blepharospasm and hemifacial spasm. Because btxA is considered as a high-cost neurological treatment, our findings could be of interest from a pharmacoeconomic point of view, especially in developing countries. Future studies should explore further the comparability of different btx formulations and serotypes based on costeffectiveness and cost-utility models.
